Farmingdale, United States
Codagenix Inc., founded in 2011, is a pioneering biotechnology company based in the United States, focused on revolutionizing vaccine and oncolytic virus development. Their proprietary platform, SAVE (Synthetic Attenuated Virus Engineering), uses sophisticated computer algorithms to create viral genomes that mimic wild strain amino acids but reduce protein production in human cells. This method yields highly attenuated viruses, which are highly effective as vaccines and treatments for solid tumors.
Currently in the clinical stage, Codagenix Inc. is advancing vaccine products targeting influenza, respiratory syncytial virus, dengue virus, and others. The company leverages cutting-edge technology to circumvent traditional and unpredictable virus attenuation methods, positioning itself at the forefront of vaccine innovation.
In its latest funding round on October 24, 2023, Codagenix Inc. secured a $5.88M grant from the U.S. Department of Defense, underscoring strategic interest and trust in their technology's potential.
